The Company is revising its previously given guidance relating to full year 2025 net revenue and Adjusted EBITDA due to the following factors: (1) the German Federal Institute for Drugs and Medical ...
Non-GAAP financial measure. Refer to "Cautionary Statement Regarding Certain Non-GAAP Measures" for further details. Click to enlarge 2025 Updated Guidance The Company is revising its previously given ...